U.S. flag An official website of the United States government
  1. Home
  2. Vaccines, Blood & Biologics
  3. Development & Approval Process (CBER)
  4. New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) for CBER-Regulated Products
  1. Development & Approval Process (CBER)

New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) for CBER-Regulated Products

New Drug Application (NDA):

Historically, CBER has regulatory jurisdiction over some NDA products. Most NDAs are reviewed by the Center for Drug Evaluation and Research (CDER).

Examples of CBER NDAs include but are not limited to:

  • Red blood cell processing solution, such as for rejuvenation of red blood cells concentrate
  • Products indicated for treatment of hypovolemia when plasma volume expansion is desired
  • Anticoagulant solution used in the collection of un-anticoagulated donor blood samples
  • Sterile bags containing anticoagulant intended for collection of umbilical cord blood
  • Products intended for use as fluid replacement and plasma volume expansion in the adjunctive treatment of certain types of shock or impending shock, such as burns, surgery, hemorrhage and other trauma
  • Solution designed to replace a proportion of the plasma used in storage of leuko-reduced apheresis platelets under standard blood banking conditions

For more information, visit the CDER website: New Drug Application (NDA)

Abbreviated New Drug Application (ANDA):

There are only a few ANDAs currently regulated at CBER, e.g., ANDAs related to blood transfusion products. Most ANDAs are reviewed by CDER.

For more information, visit the CDER website: Abbreviated New Drug Application (ANDA)

Additional Resources:

Approved New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs) with Supporting Documents for CBER-Regulated Products
Biologics Guidances
Biologics Procedures (SOPPs)
Master Files for CBER-Regulated Products
Good Review Management Principles and Practices for New Drug Applications and Biologics License Applications


Sub-Topic Paragraphs

Latest From the Commissioner

Remarks by Dr. Hahn to the National Academy of Medicine Town Hall on the COVID-19 Vaccine - 12/04/2020

Dec 04

Remarks by Dr. Hahn for the Reagan-Udall Foundation's Innovation in Regulatory Science Awards - 12/08/2020

Dec 09

Dr. Hahn's remarks to the Alliance for Health Policy Brazda Breakfast Briefing - 01/08/2021

Jan 08

Remarks by Dr. Hahn to the FDA-CMS Summit - 12/07/2020

Dec 07

Dr. Hahn’s Remarks to the Meeting of the Regulatory Affairs Professionals Society (RAPS) - 11/17/2020

Nov 19

Remarks by Dr. Hahn to the Friends of Cancer Research Annual Meeting - 11/13/2020

Nov 13

Dr. Hahn's Remarks to the GRx+Biosims 2020 Virtual Conference - 11/09/2020

Nov 09

Remarks by Frank Yiannas at the International Association for Food Protection 2020 Annual Meeting - 10/27/2020

Oct 27

Follow CBER

Division of Communication and Consumer Affairs
Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave WO71-3103
Silver Spring, MD 20993-0002

ocod@fda.hhs.gov

(800) 835-4709
(240) 402-8010

For Updates on Twitter, follow @fdacber


Back to Top